Advanced Search

 

Study ID Status Title Patient Level Data
100290 Completed A phase IIIB/IV, open-label, multi-center trial to evaluate the safety, tolerability, and efficiency of HIV-1 infected subjects switching their current protease-inhibitor therapies for a fosamprenavir therapy over 48 weeks
100327 Completed A Phase IV Randomized, Multicenter, Open-Label Study to Compare the Safety, Tolerability and Efficacy of Trizivir (abacavir 300mg, lamivudine 150mg, and zidovudine 300mg) BID vs Combivir (lamivudine 150mg and zidovudine 300mg) BID plus atazanavir 400mg QD in Antiretroviral Naive HIV-1 Infected Subjects over 48 Weeks
100732 Completed A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretroviral-Naive HIV-1 Infected Adults Over 48 Weeks
100732_144weeks Completed A Phase IIIB, Randomized, Open-Label, Multicenter Study of the Safety and Efficacy of GW433908 (700mg BID) plus ritonavir (100mg BID) Versus Lopinavir/ritonavir (400mg/100mg BID) when Administered in Combination with the Abacavir/Lamivudine (600mg/300mg) Fixed-Dose Combination Tablet QD in Antiretro
101093 Completed Pharmacogenetic Research on Hypersensitivity to Abacavir
101822 Completed A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)
102027 Completed Expanded access program for fosamprenavir (FPV, GW433908) in HIV infected subjects not responding or intolerant to the previous antiretroviral treatments.
103441 Completed A Randomised, Open-Label Study to Evaluate the Efficacy and Safety of a treatment optimisation with Trizivir during 96 weeks after a first antiretroviral treatment in HIV-1 Infected Subjects
104501 Completed Pharmacokinetic study of LEXIVA® (fosamprenavir calcium hydrate) tablet in healthy Japanese male subjects.
104774 Completed Microalbuminuria as a Predictor of the Development of Kidney Disease in HIV-Positive Patients
104807 Completed Post-Marketing Clinical Study of EPZICOM Tablet (Lamivudine / Abacavir Sulfate) – Pharmacokinetic Study in HIV-Infected Patients –
105736 Completed An Observational, Open-Label, Multicentre, Post-Marketing Surveillance Study on the Safety and Efficacy of Abacavir in Combination with Lamivudine in HIV-1 Infected, Therapy-Naïve Adults in Germany.
105816 Completed A post-marketing surveillance to monitor the safety of 3TCTM (Lamivudine 150mg) administered in Korean subjects according to the prescribing information
107362 Completed HIV Model Fixed Dosed Combination Outcomes
107484 Completed A Phase I, Randomized, Open Label, Four Arm, Two Period, Two 2X2, Crossover, Drug Interaction Study to Assess Steady-State Plasma Amprenavir and Phenytoin Pharmacokinetics following Administraction of Fosamprenavir 700mg BID + Ritonavir 100mg BID + Phenytoin 300mg QD, Fosamprenavir 700mg BID + R ...
108223 Completed A retrospective, multi-centre observational study to evaluate disease management and adverse events in adult subjects with HIV-1 infection who were withdrawn from CNA106030 due to a positive HLA-B*5701 test result.
111405 Completed A Phase I, open label, randomized, two period, one-way two sequence crossover study to evaluate the effect of darunavir/ritonavir and lopinavir/ritonavir on GSK1349572 pharmacokinetics in healthy adult subjects (ING111405).
111451 Completed A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1265744 in Healthy Male and Female Subjects and Subjects Infected with HIV
111521 Completed A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1349572 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults (ING111521)
111602 Completed A Phase I, open label, randomized, four-period crossover studyto evaluate the effects of Maalox® Advanced Maximum Strengthand One A Day® Maximum on pharmacokinetics of GSK1349572in healthy adult subjects
111603 Completed A Phase I, open label, two period, single fixed-sequence crossover study to evaluate the effect of etravirine on GSK1349572 pharmacokinetics in healthy adult subjects (ING111603)
111604 Completed A Phase I, Open Label, Single Sequence,Drug Interaction Study Evaluating Plasma GSK1349572 and Tenofovir Pharmacokinetics in Healthy Adult Subjects (ING111604)
111762 Active, not recruiting A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered with an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults
111839 Completed A Phase I, open label crossover study to evaluate the effect of etravirine on GSK1265744 pharmacokinetics in healthy adult subjects
111853 Completed An Open Label, Non-Randomized, Single dose, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1349572 20 mg, Administered as a Single Oral Suspension Dose to Healthy Adult Subjects (ING111853)